Atherosclerosis severity but not undiagnosed diabetes predicts new cardiovascular events of subjects in secondary cardiovascular prevention

被引:9
|
作者
Rizza, Stefano [1 ]
Copetti, Massimiliano [2 ]
Cardellini, Marina [1 ]
Porzio, Ottavia [1 ]
Luzi, Alessio [1 ]
Pecchioli, Chiara [1 ]
Martelli, Eugenio [4 ]
Valentini, Alessia [1 ]
Ippoliti, Arnaldo [4 ]
Romeo, Francesco [1 ]
Pellegrini, Fabio [2 ,3 ]
Lauro, Davide [1 ]
Lauro, Renato [1 ]
Federici, Massimo [1 ]
机构
[1] Univ Roma Tor Vergata, Dept Internal Med, I-00133 Rome, Italy
[2] IRCCS Casa Sollievo Sofferenza, Unit Biostat, San Giovanni Rotondo, Italy
[3] Consorzio Mario Negri Sud, Unit Biostat, Lab Clin Epidemiol Diabet & Chron Dis, Chieti, Italy
[4] Univ Roma Tor Vergata, Dept Surg, I-00133 Rome, Italy
关键词
Cardiovascular risk; Diabetes; Atherosclerosis; Inflammation; CORONARY-HEART-DISEASE; RISK; MORTALITY; MELLITUS; OUTCOMES;
D O I
10.1016/j.atherosclerosis.2012.04.019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Undiagnosed diabetes (DM2), especially in individuals that have experienced a major atherosclerotic vascular event, could increase the risk of a second major cardiovascular (CV) event. The aim of this study was to evaluate the impact of type 2 diabetes (DM2), diagnosed after a major cardiovascular event, on subsequent CV disease in high risk individuals. Methods: 411 subjects without known DM2 and with a history of a prior major CV event were followed for a second major CV event (fatal and nonfatal MI, fatal and nonfatal stroke or any arterial revascularization procedure). At baseline, each individual underwent a physical, biochemical examination, an OGTT and dosed A1c. In addition, patients were classified as having monovascular or polyvascular disease. The average follow-up duration was 31 months. Results: The incidence of second CV events was 10.70 per 100 person-years (114 events/1066 person-years). The diagnosis of occult DM2 was not associated with major CV events, either using A1c values >= 6.5%, fasting glucose >= 126 mg/dL or 2 h post-load glucose >= 200 mg/dL. Polyvascular disease was the only significant predictor of a second major CV event (HR 2.60, 95% CI 1.72-3.95) after adjustment for age, BMI, smoking status, systolic blood pressure, high-density and low-density lipoprotein cholesterol and high sensitivity C-reactive protein. Conclusion: DM2 that was newly diagnosed after established vascular atherosclerotic disease did not increase the risk of new major CV events. In our population only the polyvascular disease was able to identify the subjects at high risk for a second major cardiovascular event. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:448 / 453
页数:6
相关论文
共 50 条
  • [1] Secondary Prevention of cardiovascular Events
    Mouret, P.
    ORTHOPADE, 2019, 48 (01): : 102 - 102
  • [2] SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS
    Mora, S.
    CARDIOLOGY, 2016, 134 : 404 - 404
  • [3] Atherosclerosis and hormone replacement therapy: The role of estrogen in secondary prevention of cardiovascular events
    Sullivan, JM
    HORMONAL CARCINOGENESIS III, 2001, : 372 - 382
  • [4] THE SEVERITY OF THE METABOLIC SYNDROME AMONG ANGIOGRAPHIED CORONARY PATIENTS PREDICTS CARDIOVASCULAR EVENTS BOTH IN PATIENTS WITH DIABETES AND IN NONDIABETIC SUBJECTS
    Saely, Christoph
    Vonbank, Alexander
    Lins, Christina
    Zanolin, Daniela
    Leiherer, Andreas
    Muendlein, Axel
    Rein, Philipp
    Drexel, Heinz
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 1843 - 1843
  • [5] Subclinical atherosclerosis burden predicts cardiovascular events in individuals with diabetes and chronic kidney disease
    Ana Palanca
    Esmeralda Castelblanco
    Àngels Betriu
    Hèctor Perpiñán
    Berta Soldevila
    José Manuel Valdivielso
    Marcelino Bermúdez-Lopez
    Carlos Puig-Jové
    Manel Puig-Domingo
    Per-Henrik Groop
    Elvira Fernández
    Núria Alonso
    Didac Mauricio
    Cardiovascular Diabetology, 18
  • [6] Subclinical atherosclerosis burden predicts cardiovascular events in individuals with diabetes and chronic kidney disease
    Palanca, Ana
    Castelblanco, Esmeralda
    Betriu, Angels
    Perpinan, Hector
    Soldevila, Berta
    Manuel Valdivielso, Jose
    Bermudez-Lopez, Marcelino
    Puig-Jove, Carlos
    Puig-Domingo, Manel
    Groop, Per-Henrik
    Fernandez, Elvira
    Alonso, Nuria
    Mauricio, Didac
    CARDIOVASCULAR DIABETOLOGY, 2019, 18 (1)
  • [7] Cardiovascular risks in type 2 diabetes and secondary cardiovascular prevention
    Ducimetière, P
    DIABETES & METABOLISM, 2005, 31 (05) : 503 - 506
  • [8] Niacin for primary and secondary prevention of cardiovascular events
    Schandelmaier, Stefan
    Briel, Matthias
    Saccilotto, Ramon
    Olu, Kelechi K.
    Arpagaus, Armon
    Hemkens, Lars G.
    Nordmann, Alain J.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (06):
  • [9] Secondary prevention of cardiovascular events in PAD patients
    Poredos, P.
    Jezovnik, M. K.
    MULTIDISCIPLINARY APPROACH TO CARDIOVASCULAR DISEASES, 2016, : 27 - 30
  • [10] Aspirin for primary prevention of cardiovascular events in diabetes
    Colwell, JA
    DIABETES CARE, 2003, 26 (12) : 3349 - 3350